Teleflex Incorporated · NYSE:TFX
Teleflex — Q3 2026 Earnings Presentation
37 slides from Teleflex's earnings presentation, Nov 5, 2026
Slide 1: Teleflex Incorporated Third Quarter 2026 Earnings Conference Call
Teleflex Incorporated Third Quarter 2026 Earnings Conference Call 11/5/2026
Slide 2: Conference Call Logistics
Conference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) An audio replay of the call will be available beginning at 11:00 am Eastern Time on November 5, 2026 either on the Teleflex website or by telephone. The call c
Slide 3: Today's Speakers
Today’s Speakers Jason John Deren Lawrence Weidman Executive VP Keusch President and CEO and CFO VP, Investor Relations and Strategy Development TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026
Slide 4: Note on Forward-Looking Statements and Non-GAAP Financial Measures
Note on Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, our forecasted 2026: GAAP, pro forma adjusted revenue and pro forma adjusted constant currency revenue growth, GAAP and adjusted operating margin and GAAP and adjusted earnings pe
Slide 5: Executive Overview
Executive Overview Jason Weidman President and CEO
Slide 6: Q3'26 Performance Summary
Q3'26 Highlights Q3 ◦ Q3'26 pro forma adjusted constant currency revenue grew 3.0% year-over-year Performance ◦ Q3'26 adjusted gross margin of 66.8% and adjusted operating margin of 25.0% Summary ◦ Q3'26 adjusted EPS of $2.63, a 39.2% increase year-over-year ◦ Closed the OEM Strategic Divestiture fo
Slide 7: Innovation Updates: EZPLAZ
Innovation Updates EZPLAZTM: Building a Long-Term Growth Driver – First and only FDA-licensed freeze dried plasma; approved in late July; customer interest has been high Q3 2026 UPDATE – Stored at room temperature and ready to reconstitute in minutes – makes plasma available on the EZPLAZTM battlefi
Slide 8: Innovation Updates: Freesolve RMS
Innovation Updates FreesolveTM Resorbable Magnesium Scaffold (RMS) Breakthrough Device Designation Received – Received FDA Breakthrough Device Designation (BDD) for FreesolveTM RMS in percutaneous coronary Differentiated intervention (PCI), building on the 2024 BDD for below-the-knee (BTK) treatment
Slide 9: Q3'26 Segment Commentary of Continuing Operations
Q3'26 Segment Commentary of Continuing Operations Sales ($M) Commentary $243.5 • In Q3'26, growth was primarily driven by our intraosseous portfolio, hemostatic products, and peripheral Vascular Reported rev. growth: 4.7% access products Pro forma adj. const. curr. rev. • As expected, saw some distr
Slide 10: Q3'26 Revenue Review By Segment
Q3'26 Revenue Review By Segment Three Months Ended September 30, 2026 September 30, 2026 September 28, 2025 % Increase / (Decrease) Pro Forma Pro Forma Pro Forma Adjusted Reported Reported Reported Adjustment Adjustment Adjusted Adjustment Adjusted Revenue Growth Currency Impact Constant Revenue Rev
Slide 11: Financial Overview
Financial Overview John Deren Executive VP and CFO
Slide 12: Q3'26 Financial Review of Continuing Operations
Q3'26 Financial Review of Continuing Operations Adjusted GAAP 2025 62.3% 2025 51.5% ◦ The year-over-year adjusted gross margin increase was primarily driven by the following: Gross Margin 450 bps ◦ a 290 bps benefit from a refund related to 2026 IEEPA tariff payments ◦ and foreign currency fluctuati
Slide 13: Capital Allocation Strategy Update
Capital Allocation Strategy Update Capital return commitment • $1 billion share repurchase authorization and $800 million reduction in debt • Near-term capital return to shareholders to be primarily funded by after-tax proceeds from the Strategic Divestitures Share repurchases • From July 1, 2026 th
Slide 14: 2026 Financial Guidance
2026 Financial Guidance ◦ Maintaining 2026 pro forma adjusted constant currency revenue growth range of 3.5% to 4.5% year-over-year Revenue ◦ Reducing 2026 GAAP revenue from continuing operations growth range to 13.2% to 14.2% year-over-year due to changes in foreign currency exchange rates ◦ Increa
Slide 15: 2026 Guidance Considerations
2026 Guidance Considerations ◦ 3.5% to 4.5% pro forma adjusted constant currency revenue growth for 2026 Pro Forma Adj. CC ◦ Excludes foreign exchange, Italian payback measure, and discontinued products Revenue Growth ◦ Includes Vascular Intervention revenue for the first half of 2025 ◦ 2026 adjuste
Slide 16: 2026 Financial Guidance – Future Opportunities
2026 Financial Guidance – Future Opportunities ◦ TS/MS agreements expected to offset stranded costs on an annualized basis following close of AC/IU Strategic Divestiture Adjusted Operating ◦ Previously announced restructuring programs to result in ~$50 million of pre-tax Margin savings on an annuali
Slide 17: 2026 Financial Guidance of Continuing Operations Summary
2026 Financial Guidance of Continuing Operations Summary 2026 Guidance Low High GAAP Revenue Growth 13.2% 14.2% Impact of Vascular Intervention Pro Forma 10.0% 10.0% Impact of Discontinued Product (0.7)% (0.7)% Impact of Italian Payback Measure (0.5)% (0.5)% Base Year Adjustment (GAAP Versus Pro For
Slide 18: Forecasted 2026 Pro Forma Adjusted Revenue Reconciliation
Forecasted 2026 Pro Forma Adjusted Revenue From Continuing Operations Reconciliation 2026 Guidance 2026 Guidance 2025 Low High GAAP revenue $1,992.7 $2,256 $2,276 Vascular Intervention pro forma adjustment 199.0 — — Discontinued product adjustment (14.3) — — Italian payback measure adjustment (9.0)
Slide 19: Key Takeaways
Key Takeaways Strong Q3 Performance; Meaningful Progress on Clear Path to a Meaningful Raising FY26 Adjusted EPS Our Transformation Step-Up in 2027+ Guidance • Priorities: strengthen foundation, • Interventional integration accelerate organizational advancing with new leadership in effectiveness, el
Slide 20: Thank You!
Thank You! 20 TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026
Slide 21: Appendices
Appendices Empowering the future of healthcare
Slide 22: Non-GAAP Financial Measures
Non-GAAP Financial Measures The presentation to which these appendices are attached and the following appendices include, among other things, tables reconciling the following applicable non-GAAP financial measures to the most comparable GAAP financial measure: Pro forma adjusted revenue. This non-GA
Slide 23: Non-GAAP Financial Measures
Non-GAAP Financial Measures Adjusted diluted earnings per share. This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the impact of (i) restructuring and optimizat
Slide 24: Non-GAAP Adjustments
Non-GAAP Adjustments The following is an explanation of certain of the adjustments that are applied with respect to one or more of the non-GAAP financial measures that appear in the presentation to which these appendices are attached: Restructuring and optimization charges - Restructuring and optimi
Slide 25: Non-GAAP Adjustments
Non-GAAP Adjustments Italian payback measure - The Italian payback measure is a law that requires suppliers of medical devices to the Italian National Healthcare System to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings esta
Slide 26: Non-GAAP Adjustments
Non-GAAP Adjustments ERP implementation - These adjustments represent direct and incremental costs incurred in connection with our implementation of a new global enterprise resource planning ("ERP") solution and related IT transition costs. An implementation of this scale is a significant undertakin
Slide 27: Appendix A1 – 2026 Revenue Review By Segment
Appendix A1 – 2026 Revenue Review By Segment Nine Months Ended September 30, 2026 September 30, 2026 September 28, 2025 % Increase / (Decrease) Pro Forma Pro Forma Pro Forma Adjusted Reported Reported Reported Adjustment Adjustment Adjusted Adjustment Adjusted Revenue Growth Currency Impact Constant
Slide 28: Appendix A2 – Segment Revenue Review by Region
Appendix A2 – Segment Revenue Review by Region Three Months Ended Nine Months Ended September 30, September 28, September 30, September 28, 2026 2025 2026 2025 Reported Revenue Vascular North America $155.6 $151.9 $469.1 $444.2 Rest of World 87.9 80.6 257.5 233.4 Total 243.5 232.5 726.6 677.6 Interv
Slide 29: Appendix B1 – Reconciliation of Consolidated Statement of Income Items
Appendix B1 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) Three Months Ended September 30, 2026 Operating Income Income tax Effective Diluted earnings per share Revenue Gross margin SG&A (1) R&D (1) margin (2) before expense income tax from c
Slide 30: Appendix B2 – Reconciliation of Consolidated Statement of Income Items
Appendix B2 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) Three Months Ended September 28, 2025 (Loss) Effective Diluted (loss) Revenue Gross SG&A (1) R&D (1) Operating Income Income tax income tax earnings per share margin margin (2) before
Slide 31: Appendix B3 – Reconciliation of Consolidated Statement of Income Items
Appendix B3 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) Nine Months Ended September 30, 2026 Operating Income Income tax Effective Diluted earnings per share Revenue Gross margin SG&A (1) R&D (1) margin (2) before expense income tax from co
Slide 32: Appendix B4 – Reconciliation of Consolidated Statement of Income Items
Appendix B4 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) Nine Months Ended September 28, 2025 Diluted earnings Revenue Gross SG&A (1) R&D (1) Operating Income before Income tax Effective per share from margin margin (2) income taxes expense
Slide 33: Appendix B Tickmarks
A. Restructuring and optimization charges – For the three months ended September 30, 2026, a pre-tax restructuring benefit of $0.3 million was offset by restructuring related charges of $4.0 million. For the three months ended September 28, 2025, pre-tax restructuring charges were $1.6 million and r
Slide 34: Appendix C - 2026 Adj. Operating Margin Guidance Reconciliation
Appendix C - 2026 Adj. Operating Margin Guidance Reconciliation Forecasted GAAP Operating Margin 11.0% Estimated restructuring and optimization items 2.1% Estimated acquisition, integration and divestiture related items 1.4% Estimated other items (1.3)% Estimated ERP implementation 0.7% Estimated in
Slide 35: Appendix D - Reconciliation of Forecasted 2026 Adjusted EPS Guidance
Appendix D - Reconciliation of Forecasted 2026 Adjusted Earnings Per Share Guidance Low High Forecasted GAAP Diluted Earnings Per Share from continuing operations $2.84 $3.09 Restructuring and optimization items, net of tax $0.93 $0.93 Acquisition, integration and divestiture related items, net of t
Slide 36: 2026 Financial Review - Nine Months Ended September 30, 2026
2026 Financial Review - Nine Months Ended September 30, 2026 ◦ Pro forma adjusted revenue increased 4.2% year-over-year on a constant currency basis Global revenue growth ◦ Revenue increased 18.5% year-over-year on a GAAP basis ◦ Adjusted gross margin of 63.3%, down 80 bps year-over-year Gross margi
Slide 37: Indications and Important Safety Information for EZPLAZ
Rx Only INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR EZPLAZ™ FREEZE DRIED PLASMA INDICATIONS EZPLAZ™ Freeze Dried Plasma (FDP) is indicated for transfusion in adults when plasma is required and other plasma products are not available. Indications include: • Management of preoperative or bleeding